Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | FLT1 | P17948 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 10/20 | 1.00 |
| ▸ | FLT4 | P35916 | 6/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 0.84 |
| ▸ | SRC | P12931 | 1/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | KIF5B | P33176 | 2/20 | 0.76 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.71 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.71 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365791 | 1.00 | KDR (1.00) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL7867640 | 0.99 | KDR (0.98) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL30078372 | 0.99 | KDR (0.98) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL1468310 | 0.92 | FLT1 (0.85) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7867151 | 0.92 | FLT1 (1.00) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL21557447 | 0.91 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL1467058 | 0.91 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7864752 | 0.91 | FLT1 (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7867708 | 0.91 | FLT1 (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL7859481 | 0.91 | FLT1 (0.98) | KDRFLT1FGFR1FLT4EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119546307-A | Vascular endothelial growth factor receptor-1 (VEGFR-1) inhibitors for promoting myelination and neuroprotection | 大脑和脊髓研究所 | 2025-02-28 | — | — | CN | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346635-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÉRE) (FR) | 2025-11-13 | — | — | US | disclosed |
| EP-4547252-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2025-05-07 | — | — | EP | disclosed |
| CN-119546307-A | Vascular endothelial growth factor receptor-1 (VEGFR-1) inhibitors for promoting myelination and neuroprotection | 大脑和脊髓研究所 | 2025-02-28 | — | — | CN | disclosed |
| US-12185774-B2 | Methods and devices for preventing viral transmission | VOMARIS INNOVATIONS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346635-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | FLT1, KDR, FLT4 | KDR 2/4885FLT1 1/4885FGFR1 50/4885 |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SLC5A2, GCKR, IAPP | KDR 2859/4885FLT1 3662/4885FGFR1 3131/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885FLT1 4/4885FGFR1 1/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDR 2076/4885FLT1 1335/4885FGFR1 350/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDR 2076/4885FLT1 1335/4885FGFR1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.